Why GSK's Shingrix is reshaping the shingles vaccine market

Reviewed: ad hoc news Software & Services desk. Edited and checked on 2026-06-18, 04:43. Details in the imprint.

Shingrix is the kind of vaccine you remember, not because of the injection itself, but because it promises to keep a burning, stabbing shingles rash from ever flaring up in the first place. GSK positions it clearly for adults who really want to avoid that pain.

What Shingrix is designed to do

Shingrix is a recombinant, adjuvanted vaccine that targets herpes zoster, better known as shingles, which is caused by reactivation of the varicella zoster virus years after chickenpox. It is given as a two-dose series, typically two to six months apart.

Unlike the older live-attenuated shingles vaccine, Shingrix uses a non-live antigen combined with GSK's AS01B adjuvant system to trigger a stronger immune response in older adults. That design makes it suitable for many people with age-related immune decline, subject to medical advice.

Efficacy data that changed guidelines

In large phase 3 trials, Shingrix showed vaccine efficacy of around 97 percent against shingles in adults aged 50 to 69 years, and about 91 percent in those 70 and older. Protection against postherpetic neuralgia, the long-lasting nerve pain complication, was similarly high.

These numbers were strong enough that health authorities such as the US CDC recommended Shingrix as the preferred shingles vaccine for immunocompetent adults 50 years and older. Several countries have since integrated it into national vaccination programs or reimbursement schemes.

How a Shingrix appointment feels

On vaccination day, Shingrix usually comes as a small vial combo that the nurse mixes before drawing up a cloudy suspension. The injection goes into the upper arm muscle and takes only a few seconds, but many people report noticeable soreness afterward.

Short-term side effects like pain at the injection site, fatigue, muscle aches and sometimes a low-grade fever are common, especially after the second dose. Most resolve within two or three days, but it is wise not to schedule heavy physical work right after.

Where Shingrix is available and who pays

Shingrix is already widely available in the United States, Canada, parts of Europe and several Asia-Pacific markets through pharmacies, clinics and physicians. In some countries it is fully or partly reimbursed for people above a certain age or with specific risk factors.

List prices vary by market and channel, and in the US a single dose can run to several hundred dollars before insurance, according to pharmacy data. Many health plans, however, cover the vaccine under preventive services for older adults.

Why it matters for GSK and investors

For GSK, Shingrix has grown into a central product in its vaccines portfolio, contributing meaningful revenue growth as new markets open and existing ones expand recommendations. Management has repeatedly pointed to shingles vaccination as a durable long-term opportunity.

Shares of GSK (ISIN GB0009252882) trade in London on the LSE, where the company is followed closely by investors watching how vaccines like Shingrix balance older respiratory franchises and newer specialty medicines.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.